Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects

Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells

(2018) Marije J. Veenstra et al.   Oncotarget

Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids

(2017) Ivana Sullivan et al.   EUROPEAN JOURNAL OF CANCER

High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study

(2017) Andrea Giustina et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Somatostatin Receptor Antagonists for Imaging and Therapy

(2017) Melpomeni Fani et al.   JOURNAL OF NUCLEAR MEDICINE

Biodistribution, Pharmacokinetics, and Dosimetry of 177 Lu-, 90 Y-, and 111 In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177 Lu-DOTATATE: The Mass Effect

(2017) Guillaume P. Nicolas et al.   JOURNAL OF NUCLEAR MEDICINE

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

(2017) Jonathan Strosberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors

(2017) Anne Couvelard et al.   PANCREAS

Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors

(2017) James Yao et al.   OncoTargets and Therapy

Everolimus treatment for neuroendocrine tumors: latest results and clinical potential

(2017) Sara Pusceddu et al.   Therapeutic Advances in Medical Oncology

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

(2017) Arvind Dasari et al.   JAMA Oncology

Neuroendocrine Tumors

(2017)   Journal of the National Comprehensive Cancer Network

Peptide receptor radionuclide therapy of neuroendocrine tumours

(2016) Tessa Brabander et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

(2016) Martyn E Caplin et al.   ENDOCRINE-RELATED CANCER

Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression

(2016) Gerard V. Walls et al.   ENDOCRINOLOGY

Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors

(2016) Omid Fotouhi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Upregulation of Key Molecules for Targeted Imaging and Therapy

(2016) V. F. Taelman et al.   JOURNAL OF NUCLEAR MEDICINE

Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions

(2016) C. M. Deroose et al.   JOURNAL OF NUCLEAR MEDICINE

Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells

(2016) Roxanne C.S. van Adrichem et al.   NEUROENDOCRINOLOGY

ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

(2016) M. Pavel et al.   NEUROENDOCRINOLOGY

ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum

(2016) B. Niederle et al.   NEUROENDOCRINOLOGY

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival

(2016) Anja Rinke et al.   NEUROENDOCRINOLOGY

Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer

(2016) Lisa Bodei et al.   SEMINARS IN NUCLEAR MEDICINE

The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs

(2016) Seung Tae Kim et al.   Journal of Cancer

177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model

(2016) Seval Beykan et al.   EJNMMI Research

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

(2015) M. E. Caplin et al.   ANNALS OF ONCOLOGY

The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis

(2015) Sebastian Richards-Taylor et al.   JOURNAL OF CLINICAL PATHOLOGY

Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models

(2015) S. U. Dalm et al.   JOURNAL OF NUCLEAR MEDICINE

Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition

(2015) Mauro Cives et al.   NEUROENDOCRINOLOGY

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

(2015) Edward Wolin et al.   Drug Design Development and Therapy

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?

(2015) Kalliopi Domvri et al.   Journal of Cancer

Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours

(2014) V. Ramundo et al.   CLINICAL ENDOCRINOLOGY

Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures

(2014) A. Mohamed et al.   ENDOCRINE-RELATED CANCER

Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors

(2014) Andrea Giustina et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Parathyroid Hormone-Related Peptide (PTHrP) Secretion by Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Clinical Features, Diagnosis, Management, and Follow-Up

(2014) Kimberly Kamp et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study

(2014) D. Wild et al.   JOURNAL OF NUCLEAR MEDICINE

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

(2014) Martyn E. Caplin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial

(2014) Mônica R Gadelha et al.   Lancet Diabetes & Endocrinology

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study

(2012) Larry K Kvols et al.   ENDOCRINE-RELATED CANCER

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

(2012) Annamaria Colao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy

(2011) Gherardo Mazziotti et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible

(2011) D. Wild et al.   JOURNAL OF NUCLEAR MEDICINE

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial

(2009) Andrea Giustina et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan)

(2009) N. Hillman et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies

(2009) Gherardo Mazziotti et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

(2009) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines

(2008) Mark Kidd et al.   CANCER

Differential Effects of Octreotide and Pasireotide on Somatostatin Receptor Internalization and Traffickingin Vitro

(2008) Sarah Lesche et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Cell Growth Inhibition and Functioning of Human Somatostatin Receptor Type 2 Are Modulated by Receptor Heterodimerization

(2008) Michael Grant et al.   MOLECULAR ENDOCRINOLOGY